First HER2/4-1BB Bispecific Molecule Shows Clinical Activity in HER2+ Cancers

PRS-343, a HER2/4-1BB targeting bispecific construct, is well-tolerated and demonstrated anti-tumor activity in heavily pre-treated patient population across multiple tumor types.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news